Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection
摘要:
Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.
Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection
摘要:
Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.
[EN] AMINOTHIAZOLES AND THEIR USES<br/>[FR] AMINOTHIAZOLES ET LEURS UTILISATIONS
申请人:NOVARTIS AG
公开号:WO2009074605A1
公开(公告)日:2009-06-18
The present application describes organic compounds that are useful for the treatment, prevention, and/or amelioration of diseases particularly bacterial infections, formula (I), and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, atropisomers or racemates thereof, including the pyridine N-oxide thereof;
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.
本申请描述了有机化合物,可用于治疗、预防和/或改善疾病,特别是细菌感染。
US20140274878A1
申请人:——
公开号:US20140274878A1
公开(公告)日:2014-09-18
AMINOTHIAZOLES AND THEIR USES
申请人:Bushell Simon
公开号:US20170015704A1
公开(公告)日:2017-01-19
The present application describes organic compounds of Formula (I)
and pharmaceutical compositions thereof, and their use for the treatment, prevention and/or amelioration of diseases, particularly bacterial infections.